Palovarotene therapy reduces heterotopic ossification (HO) in children and adults with fibrodysplasia ossificans progressiva (FOP), indicates the third interim analysis of the MOVE trial, conducted after at least 18 months of follow-up.

An international, 3-year study of people with fibrodysplasia ossificans progressive (FOP) has mapped the natural history of the disease and shown that the greatest levels of progression occur during childhood and early adulthood.

An international survey of patients with fibrodysplasia ossificans progressiva (FOP) and their families has shown that decreased joint function is associated with reduced quality of life (QoL), greater reliance on living adaptations, and economic implications.

Treatment with the retinoic acid receptor (RAR)-gamma agonist palovarotene may prevent heterotopic ossification (HO) during a fibrodysplasia ossificans progressiva (FOP) flare-up, phase 2 study data suggest.

Swiss researchers have identified a novel compound that selectively inhibits activin receptor-like kinase 2 (ALK2) and may be a future candidate for the treatment of fibrodysplasia ossificans progressive (FOP).

A meeting of key stakeholders in the fibrodysplasia ossificans progressiva (FOP) community has highlighted the major challenges and opportunities for improvement in care pathways and patient involvement in research.

Since the start of the COVID-19 pandemic, individuals with fibrodysplasia ossificans progressiva (FOP) have reported decreased satisfaction with their social activities, declining mental health, and a reduction in dental visits, US research shows.

US researchers have identified three plasma-soluble biomarkers that may reflect acute and chronic inflammatory states in people with fibrodysplasia ossificans progressiva (FOP).

Drugs that selectively induce apoptosis of senescent cells may be effective candidates for the treatment of fibrodysplasia ossificans progressiva (FOP) flare-ups via the inhibition of tissue reprogramming and subsequent prevention of endochondral heterotopic ossification (HO), preclinical study findings indicate.

The prevalence of fibrodysplasia ossificans progressiva (FOP) in the US is higher than previously believed, according to research published in the Orphanet Journal of Rare Diseases.

Children treated for fibrodysplasia ossificans progressiva (FOP) with imatinib in an off-on-off-on (O4) regimen have fewer flare-ups, decreased swelling, and improved function when on versus off treatment, US researchers report.

Experimental data suggest that the tyrosine kinase inhibitor saracatinib may be a candidate for the treatment of fibrodysplasia ossificans progressiva (FOP), via its inhibition of activin receptor-like kinase (ALK)2.

A detailed analysis of radiographs from individuals with ACVR1R206H -mutated fibrodysplasia ossificans progressiva (FOP) has found that great toe malformations result from monophalangeal and biphalangeal phenotypes.

Results of two trials presented at the ASBMR 2020 Annual Meeting Virtual Event show promising new options for the treatment of fibrodysplasia ossificans progressiva (FOP).

Patients with fibrodysplasia ossificans progressiva (FOP) wait an average of 1.5 years to receive a correct diagnosis, with more than half initially misdiagnosed, show data from the international FOP registry.